200 related articles for article (PubMed ID: 38177530)
1. MYSM1 acts as a novel co-activator of ERα to confer antiestrogen resistance in breast cancer.
Luan R; He M; Li H; Bai Y; Wang A; Sun G; Zhou B; Wang M; Wang C; Wang S; Zeng K; Feng J; Lin L; Wei Y; Kato S; Zhang Q; Zhao Y
EMBO Mol Med; 2024 Jan; 16(1):10-39. PubMed ID: 38177530
[TBL] [Abstract][Full Text] [Related]
2. An H3K4me3 reader, BAP18 as an adaptor of COMPASS-like core subunits co-activates ERα action and associates with the sensitivity of antiestrogen in breast cancer.
Sun G; Wang C; Wang S; Sun H; Zeng K; Zou R; Lin L; Liu W; Sun N; Song H; Liu W; Zhou T; Jin F; Shan Z; Zhao Y
Nucleic Acids Res; 2020 Nov; 48(19):10768-10784. PubMed ID: 32986841
[TBL] [Abstract][Full Text] [Related]
3. Apigenin inhibits antiestrogen-resistant breast cancer cell growth through estrogen receptor-alpha-dependent and estrogen receptor-alpha-independent mechanisms.
Long X; Fan M; Bigsby RM; Nephew KP
Mol Cancer Ther; 2008 Jul; 7(7):2096-108. PubMed ID: 18645020
[TBL] [Abstract][Full Text] [Related]
4. USP22 positively modulates ERα action via its deubiquitinase activity in breast cancer.
Wang S; Zhong X; Wang C; Luo H; Lin L; Sun H; Sun G; Zeng K; Zou R; Liu W; Sun N; Song H; Liu W; Zhang Q; Liao Z; Teng X; Zhou T; Sun X; Zhao Y
Cell Death Differ; 2020 Nov; 27(11):3131-3145. PubMed ID: 32494025
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of histone methyltransferase DOT1L silences ERα gene and blocks proliferation of antiestrogen-resistant breast cancer cells.
Nassa G; Salvati A; Tarallo R; Gigantino V; Alexandrova E; Memoli D; Sellitto A; Rizzo F; Malanga D; Mirante T; Morelli E; Nees M; Åkerfelt M; Kangaspeska S; Nyman TA; Milanesi L; Giurato G; Weisz A
Sci Adv; 2019 Feb; 5(2):eaav5590. PubMed ID: 30775443
[TBL] [Abstract][Full Text] [Related]
6. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD
Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366
[TBL] [Abstract][Full Text] [Related]
7. Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
Salvati A; Melone V; Sellitto A; Rizzo F; Tarallo R; Nyman TA; Giurato G; Nassa G; Weisz A
Breast Cancer Res; 2022 Jul; 24(1):52. PubMed ID: 35850772
[TBL] [Abstract][Full Text] [Related]
8. Chromatin-binding deubiquitinase MYSM1 acts in haematopoietic progenitors to control dendritic cell development and to program dendritic cell responses to microbial stimulation.
Mousa M; Liang Y; Tung LT; Wang H; Krawczyk C; Langlais D; Nijnik A
Immunology; 2024 May; 172(1):109-126. PubMed ID: 38316548
[TBL] [Abstract][Full Text] [Related]
9. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
10. Endocrine resistant breast cancer cells with loss of ERα expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage.
Yu S; Gong X; Ma Z; Zhang M; Huang L; Zhang J; Zhao S; Zhu T; Yu Z; Chen L
Cell Oncol (Dordr); 2020 Feb; 43(1):65-80. PubMed ID: 31701491
[TBL] [Abstract][Full Text] [Related]
11. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.
Wu Y; Zhang Z; Cenciarini ME; Proietti CJ; Amasino M; Hong T; Yang M; Liao Y; Chiang HC; Kaklamani VG; Jeselsohn R; Vadlamudi RK; Huang TH; Li R; De Angelis C; Fu X; Elizalde PV; Schiff R; Brown M; Xu K
Cancer Res; 2018 Feb; 78(3):671-684. PubMed ID: 29212856
[TBL] [Abstract][Full Text] [Related]
12. Deubiquitinase MYSM1 in the Hematopoietic System and beyond: A Current Review.
Fiore A; Liang Y; Lin YH; Tung J; Wang H; Langlais D; Nijnik A
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32344625
[TBL] [Abstract][Full Text] [Related]
13. Antiestrogen Resistant Cell Lines Expressing Estrogen Receptor α Mutations Upregulate the Unfolded Protein Response and are Killed by BHPI.
Mao C; Livezey M; Kim JE; Shapiro DJ
Sci Rep; 2016 Oct; 6():34753. PubMed ID: 27713477
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
Li Y; Meeran SM; Patel SN; Chen H; Hardy TM; Tollefsbol TO
Mol Cancer; 2013 Feb; 12():9. PubMed ID: 23379261
[TBL] [Abstract][Full Text] [Related]
15. MYSM1 inhibits human colorectal cancer tumorigenesis by activating miR-200 family members/CDH1 and blocking PI3K/AKT signaling.
Chen X; Wang W; Li Y; Huo Y; Zhang H; Feng F; Xi W; Zhang T; Gao J; Yang F; Chen S; Yang A; Wang T
J Exp Clin Cancer Res; 2021 Oct; 40(1):341. PubMed ID: 34706761
[TBL] [Abstract][Full Text] [Related]
16. PSMD14 stabilizes estrogen signaling and facilitates breast cancer progression via deubiquitinating ERα.
Yang P; Yang X; Wang D; Yang H; Li Z; Zhang C; Zhang S; Zhu J; Li X; Su P; Zhuang T
Oncogene; 2024 Jan; 43(4):248-264. PubMed ID: 38017133
[TBL] [Abstract][Full Text] [Related]
17. BRCA1-mimetic compound NSC35446.HCl inhibits IKKB expression by reducing estrogen receptor-α occupancy in the IKKB promoter and inhibits NF-κB activity in antiestrogen-resistant human breast cancer cells.
Nathan S; Ma Y; Tomita YA; De Oliveira E; Brown ML; Rosen EM
Breast Cancer Res Treat; 2017 Dec; 166(3):681-693. PubMed ID: 28808806
[TBL] [Abstract][Full Text] [Related]
18. Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells.
Kim SS; Lee MH; Lee MO
Breast Cancer Res Treat; 2020 Feb; 180(1):45-54. PubMed ID: 31897900
[TBL] [Abstract][Full Text] [Related]
19. Identification of MYST3 as a novel epigenetic activator of ERα frequently amplified in breast cancer.
Yu L; Liang Y; Cao X; Wang X; Gao H; Lin SY; Schiff R; Wang XS; Li K
Oncogene; 2017 May; 36(20):2910-2918. PubMed ID: 27893709
[TBL] [Abstract][Full Text] [Related]
20. VAV3 mediates resistance to breast cancer endocrine therapy.
Aguilar H; Urruticoechea A; Halonen P; Kiyotani K; Mushiroda T; Barril X; Serra-Musach J; Islam A; Caizzi L; Di Croce L; Nevedomskaya E; Zwart W; Bostner J; Karlsson E; Pérez Tenorio G; Fornander T; Sgroi DC; Garcia-Mata R; Jansen MP; García N; Bonifaci N; Climent F; Soler MT; Rodríguez-Vida A; Gil M; Brunet J; Martrat G; Gómez-Baldó L; Extremera AI; Figueras A; Balart J; Clarke R; Burnstein KL; Carlson KE; Katzenellenbogen JA; Vizoso M; Esteller M; Villanueva A; Rodríguez-Peña AB; Bustelo XR; Nakamura Y; Zembutsu H; Stål O; Beijersbergen RL; Pujana MA
Breast Cancer Res; 2014 May; 16(3):R53. PubMed ID: 24886537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
